Overview

  • Product nameAnti-IL6 antibody
    See all IL6 primary antibodies
  • Description
    Goat polyclonal to IL6
  • Tested applicationsSuitable for: WB, ELISA, Neutralisingmore details
  • Species reactivity
    Reacts with: Rat
  • Immunogen

    Highly pure (>98%) recombinant rat IL-6 (rat Interleukin-6)

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab9770 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent concentration. To detect rIL-6 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant rIL-6 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
ELISA Use at an assay dependent concentration. To detect rIL-6 by direct ELISA (using 100µl/well antibody solution) a concentration of at least 0.5µg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant rIL-6.
Neutralising Use at an assay dependent concentration. To yield one-half maximal inhibition [ND50] of the biological activity of rIL-6 (0.1 ng/ml), a concentration of 0.002 0.005 µg/ml of this antibody is required.

Target

  • FunctionCytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.
  • Involvement in diseaseGenetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
    Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.
  • Sequence similaritiesBelongs to the IL-6 superfamily.
  • Post-translational
    modifications
    N- and O-glycosylated.
  • Cellular localizationSecreted.
  • Information by UniProt
  • Database links
  • Alternative names
    • Interleukin BSF 2 antibody
    • B cell differentiation factor antibody
    • B cell stimulatory factor 2 antibody
    • B-cell stimulatory factor 2 antibody
    • BSF 2 antibody
    • BSF-2 antibody
    • BSF2 antibody
    • CDF antibody
    • CTL differentiation factor antibody
    • Hepatocyte stimulatory factor antibody
    • HGF antibody
    • HSF antibody
    • Hybridoma growth factor antibody
    • Hybridoma growth factor Interferon beta-2 antibody
    • IFN-beta-2 antibody
    • IFNB2 antibody
    • IL 6 antibody
    • IL-6 antibody
    • IL6 antibody
    • IL6_HUMAN antibody
    • Interferon beta 2 antibody
    • Interferon beta-2 antibody
    • Interleukin 6 antibody
    • Interleukin 6 (interferon beta 2) antibody
    • Interleukin BSF 2 antibody
    • Interleukin-6 antibody
    see all

Anti-IL6 antibody images

  • IL-6-induced collagen synthesis during hypertrophy in vivo and in vitro.
    Serum IL-6 concentration was measured by ELISA on day 15 after renal artery ligation in rats, and results show a significant increase in secreted IL-6 level in the serum of renal artery-ligated (L) animals (721.42 ± 34.45 pg/ml) compared to sham-operated controls (39.33 ± 12.96 pg/ml), which was reduced significantly (48.1%) with neutralizing IL-6 antibody (L+N-IL-6Ab)(ab9770) treatment (10 µg/animal; on alternate days after renal artery ligation till sacrifice).

    Results are expressed as the ±S.E. of three independent experiments. **, p < 0.01 with respect to Sham; ††, p < 0.01 with respect to ligated; n = 10 in each group.

References for Anti-IL6 antibody (ab9770)

This product has been referenced in:
  • Mir SA  et al. Inhibition of Signal Transducer and Activator of Transcription 3 (STAT3) Attenuates Interleukin-6 (IL-6)-induced Collagen Synthesis and Resultant Hypertrophy in Rat Heart. J Biol Chem 287:2666-77 (2012). Neutralising ; Rat . Read more (PubMed: 22157761) »
  • Wang GY  et al. IL-17 eliminates the therapeutic effects of myelin basic protein-induced nasal tolerance in experimental autoimmune encephalomyelitis by activating IL-6. Scand J Immunol 68:589-97 (2008). Neutralising ; Rat . Read more (PubMed: 19055697) »

See all 2 Publications for this product

Product Wall

Thank you for your enquiry.

As stated on the datasheet, the anti-IL6 antibody ab9770 should be stored at +4ºC.
We do not have set expiration dates for our products. Most antibodies are stable and can last for anywhere from a few month...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"